Lipid metabolism-MAFLD crosstalk: mechanisms and therapy - Takeaways - MDSpire

Lipid metabolism-MAFLD crosstalk: mechanisms and therapy

  • By

  • Bojia Li

  • Shengai Piao

  • Yin Fu

  • Qiang Fu

  • Peiyao Qin

  • Weitai Kong

  • Yidi Ma

  • Zhe Zhang

  • Xue Fang

  • Xiaoyang Hu

  • March 18, 2026

  • 0 min

Share

  • 1

    MAFLD is the most prevalent chronic liver disorder, affecting approximately 25% of adults and linked to metabolic dysfunctions like obesity and diabetes.

  • 2

    Disruption of hepatic lipid metabolism is a key factor in the onset and progression of MAFLD, leading to insulin resistance and inflammation.

  • 3

    Specific lipid species, such as ceramides and diacylglycerols, play significant roles in MAFLD pathophysiology by promoting oxidative stress and fibrosis.

  • 4

    Recent research emphasizes a network-based approach to lipid metabolism, suggesting that targeting toxic lipids may offer new therapeutic strategies for MAFLD.

  • 5

    Effective treatment for MAFLD requires understanding the complex interactions of lipid species and their impact on metabolic health and liver function.

Original Source(s)

Lipid metabolism-MAFLD crosstalk: mechanisms and therapy

  • by Bojia Li, Shengai Piao, Yin Fu, Qiang Fu, Peiyao Qin, Weitai Kong, Yidi Ma, Zhe Zhang, Xue Fang, Xiaoyang Hu

  • March 18, 2026

Related Content

Optimizing healthcare resources in pyogenic liver abscess: a dual-threshold HDL-CRP model for predicting hospitalization duration across multi-cohorts

Borderline Liver Enzyme Patterns and Their Metabolic–Inflammatory Signatures: An Observational Outpatient Study

FDA Approves New Option in Obesity

The Allurion Gastric Balloon System is now authorized by the US Food and Drug Administration for short-term weight loss in adults aged 22 to 65 years with obesity and a body mass index of 30 to 40 kg/m2.